Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression

Abstract excerpt

Significance High-risk neuroblastoma remains a therapeutic challenge, and adjuvant retinoic acid (RA) treatment shows poor efficacy. We demonstrate that combined treatment with 5-Aza-deoxycytidine (AZA) and RA impedes neuroblastoma growth and induces a transcriptional response characterized by high levels of the HIF2α transcription factor. This approach targets high-risk neuroblastoma that responds poorly to RA....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer, Hypoxia, and Metabolism
• Share to Glioma Diagnosis and Treatment
• Share to Neuroblastoma Research and Treatments